[A23-53] Sotorasib (NSCLC) – Addendum to Commission A23-06
Last updated 03.08.2023
Project no.:
A23-53
Commission:
Commission awarded on 06.06.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with advanced non-small cell lung cancer with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy
Result of dossier assessment:
Unchanged after addendum
- After first-line therapy with cytotoxic chemotherapy: added benefit not proven
- After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-06 | Sotorasib (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-08-03 A G-BA decision was published.
G-BA documents on this decision